Breaking News Instant updates and real-time market news.

AQST

Aquestive Therapeutics

$10.12

-3.05 (-23.16%)

, RDY

Dr. Reddy's

$36.37

-0.11 (-0.30%)

13:17
11/21/18
11/21
13:17
11/21/18
13:17

Aquestive under pressure after generic Suboxone patent decision

Shares of Aquestive Therapeutics (AQST) are sliding after Dr. Reddy's Laboratories (RDY) announced that the U.S. Court of Appeals for the Federal Circuit issued a decision in favor of the latter, vacating the District Court's preliminary injunction that had prohibited Dr. Reddy's from selling its generic version of Indivior's Suboxone. While noting that the Aquestive selloff appears "meaningfully overdone," RBC Capital analyst Randall Stanicky believes this will impact the milestones that the company receives from Indivior, with the remaining milestones now unlikely. Meanwhile, his peer at BMO Capital sees the situation as fluid and "very manageable." BUPRENORPHINE, NALOXONE LITIGATION: Last night, Dr. Reddy's Laboratories along with its subsidiaries announced that the U.S. Court of Appeals for the Federal Circuit issued a decision in favor of Dr. Reddy's Laboratories, concluding that Indivior had not shown that it is likely to succeed on the merits of its infringement case on U.S. Patent No. 9,931,305. This decision vacates the District Court's preliminary injunction that had prohibited Dr. Reddy's from selling its generic version of Suboxone sublingual film. As a result of the ruling, Dr. Reddy's will resume its launch activities "as soon as permitted". In a statement following the news, Aquestive Therapeutics said that, "While we are disappointed by the court's decision, we will continue to work with Indivior to vigorously pursue ongoing infringement cases against DRL and other generic manufacturers in order to protect the Suboxone patent portfolio. [Yesterday's] action does nothing to change the validity and assertability of any of the patents in our portfolio." AQUESTIVE SELLOFF OVERDONE: In a research note to investors, RBC Capital's Stanicky argued that the decision to lift the preliminary injunction on Dr. Reddy's launching a generic version of Suboxone will impact the milestones that Aquestive receives from Indivior, with the remaining milestones now unlikely. However, he noted that Suboxone in total comprises about $3 per share in value in his model, which is meaningfully less than the two-day selloff of $7 in the stock, which makes the pullback "meaningfully overdone." Looking ahead, the analyst believes the focus for Aquestive is on the proprietary side of its business, including the recent launch of Sympazan oral film. Stanicky reiterated an Outperform rating and $24 price target on Aquestive shares. LOSS ON SUBOXONE APPEAL 'MANAGEABLE': Also commenting on the news, BMO Capital analyst Gary Nachman said that while the appeals court ruling "disappointing and surprising," and could trigger an at-risk launch by Dr. Reddy's, the situation is fluid and "very manageable." Acknowledging that there is "certainly a possibility" Indivior and Dr. Reddy's could settle, the analyst also noted that it is not completely clear if that would trigger accelerated launches of generic Suboxone from Mylan (MYL) and Endo International (ENDP)/Par. Overall, Nachman believes that Aquestive's ex-U.S. Suboxone revenue, while currently small, is a much bigger driver of long-term value. The analyst reiterated an Outperform rating and $26 price target on Aquestive shares. PRICE ACTION: In afternoon trading, shares of Aquestive have dropped over 23% to $10.11, while Dr. Reddy's stock is fractionally down to $36.36.

AQST

Aquestive Therapeutics

$10.12

-3.05 (-23.16%)

RDY

Dr. Reddy's

$36.37

-0.11 (-0.30%)

MYL

Mylan

$33.29

-0.65 (-1.92%)

ENDP

Endo

$12.39

-0.14 (-1.12%)

  • 27

    Nov

  • 02

    Dec

  • 04

    Dec

  • 19

    Jan

AQST Aquestive Therapeutics
$10.12

-3.05 (-23.16%)

09/13/18
WEDB
09/13/18
INITIATION
Target $33
WEDB
Outperform
Aquestive Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst Liana Moussatos started coverage of Aquestive Therapeutics with an Outperform rating and $33 price target. The analyst considers Aquestive Therapeutics to be an opportunity to invest in proprietary PharmFilm technology being leveraged to develop a pipeline of 10 drugs and candidates and to provide an oral alternative in patients having difficulty swallowing pills or only having invasive options like injections.
11/19/18
JMPS
11/19/18
NO CHANGE
Target $31
JMPS
Outperform
Aquestive CRL for 'peripheral' program has no read-through, says JMP Securities
After the FDA issued a CRL for Aquestive Therapeutics' tadalafil oral film candidate, JMP Securities analyst Jason Butler said he did not have this "peripheral" product in his valuation for Aquestive shares and he does not believe it is a major focus for investors. The issues raised by FDA appear specific to this product and he does not see any negative read-through to the company's other programs, Butler tells investors. He maintains an Outperform rating and $31 price target on Aquestive shares.
11/21/18
RBCM
11/21/18
NO CHANGE
Target $24
RBCM
Outperform
Aquestive selloff on generic Suboxone decision overdone, says RBC Capital
RBC Capital analyst Randall Stanicky attributes the added pressure on Aquestive Therapeutics (AQST) shares to yesterday's decision to lift the preliminary injunction on Dr. Reddy's (RDY) launching a generic version of Suboxone. He notes this will impact the milestones that Aquestive receives from Indivior, with the remaining milestones now unlikely. However, he notes that Suboxone in total comprises about $3 per share in value in his model, which is meaningfully less than the two-day selloff of $7 in the stock, which makes the pullback "meaningfully overdone" in his view. Stanicky has an Outperform rating on Aquestive shares with a $24 price target.
11/21/18
BMOC
11/21/18
NO CHANGE
Target $26
BMOC
Outperform
BMO says Aquestive loss on Suboxone appeal disappointing but manageable
BMO Capital analyst Gary Nachman noted that Aquestive Therapeutics (AQST) partner Indivior lost an appeals court ruling regarding the preliminary injunction that previously prevented Dr. Reddy's (RDY) from selling its generic version of Suboxone sublingual film. While he said the decision is disappointing and surprising, and could trigger an at-risk launch by Dr. Reddy's, Nachman sees the situation as fluid and "very manageable." There is certainly a possibility Indivior and Dr. Reddy's could settle, said the analyst, who adds that ex-U.S. Suboxone revenue, while currently small, is a much bigger driver of long-term value. Nachman has an Outperform rating and $26 price target on Aquestive shares.
RDY Dr. Reddy's
$36.37

-0.11 (-0.30%)

03/27/18
EVER
03/27/18
NO CHANGE
Target $155
EVER
Outperform
Evercore sees higher chances of Revlimid patent settlement for Celgene
Evercore ISI analyst Umer Raffat believes the odds of a Revlimid patent settlement between Celgene (CELG) and Dr. Reddy's (RDY) have gone up "considerably" following a recent court filing. The filing, according to the analyst, shows Dr. Reddy's agreed to resolve claims construction issues, which he believes "implies a clear alignment in thought process between both sides." A potential settlement on Revlimid remains the biggest catalyst on Celgene in 2018, and could lead a quick re-rating in the valuation multiple, Raffat tells investors in a research note. He keeps Celgene as his top pick for 2018 with an Outperform rating and $155 price target.
05/29/18
RHCO
05/29/18
NO CHANGE
Target $96
RHCO
Hold
Celgene price target lowered to $96 from $106 at SunTrust
SunTrust analyst Yatin Suneja lowered his price target on Celgene (CELG) to $96 after last week's R&D meeting hosted by the management, which "highlighted" the importance of the multiple myeloma program to the company, its research into the mechanism of iMiD drugs, and its pursuit of anti-B-cell maturation antigen in treatment function. The analyst believes that while the company can sustain its position of leadership in myeloma, he is concerned with the overhang on the stock coming from intellectual property litigation on Revlimid, anticipating the stock to remain rangebound until next week's likely generic Revlimid settlement with Dr. Reddy's (RDY).
MYL Mylan
$33.29

-0.65 (-1.92%)

11/15/18
11/15/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Mylan (MYL) upgraded to Buy from Hold at Argus with analyst Jasper Hellweg saying the stock appears to be close to an inflection after several quarters of underperformance. 2. CopyTele (COPY) upgraded to Outperform from Market Perform at BMO Capital. 3. Voyager Therapeutics (VYGR) upgraded to Strong Buy from Outperform at Raymond James. 4. Athenex (ATNX) upgraded to Overweight from Neutral at JPMorgan with analyst Leon Chik saying more clinical data and progress in new drug trials should boost investor sentiment in 2019. 5. Coty (COTY) upgraded to Outperform from Market Perform at BMO Capital with analyst Shannon Coyne saying that her downgrade in August was driven by concerns around the company's supply chain issues, but believes that these factors have now been fully priced in after the management withdrew its guidance and consensus earnings have been pulled back by about 30%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/15/18
ARGS
11/15/18
UPGRADE
Target $42
ARGS
Buy
Mylan upgraded to Buy from Hold at Argus
Argus analyst Jasper Hellweg upgraded Mylan to Buy with a price target of $42, saying the stock appears to be close to an inflection after several quarters of underperformance. The analyst points to the company's Q3 earnings beat and its gross margin expansion of 280bps. Hellweg further cites Mylan's launch of a "record number of new generic and biosimilar products this year, significantly diversifying its portfolio" whereby no single product now accounts for more than 3% of revenue. The analyst also keeps his FY18 EPS view at $4.73 and nudges his FY19 outlook higher by 2c to $5.28 while noting the company's forward earnings multiple of 6.8-times, which is near the low end of its 5.8- to 16.3-times historical average.
11/06/18
WELS
11/06/18
UPGRADE
Target $40
WELS
Outperform
Wells upgrades Mylan to Outperform, sees more upside after today's rally
Wells Fargo analyst David Maris upgraded Mylan (MYL) to Outperform from Market Perform with an unchanged price target of $40. The stock in afternoon trading is up 18%, or $5.76, to $37.13. Mylan shares have underperformed the S&P 500 Index for the year-to-date, one year, two year, and five year periods and the shares trade at a discount to peer Teva (TEVA), Maris tells investors in a research note titled "Concerns Abound, but Valuation Attractive." The analyst, however, believes Mylan is positioned for near-term outperformance after the company maintained its 2018 earnings guidance. Maris previously saw risk to second half of 2018 estimates, but with today's Q3 results, he now believes the risk to the downside to Q4 estimates is lower than previously thought. Further, Mylan's statement that Q4 guidance can be achieved with or without new approvals "provides some upside to sentiment" if generic Advair or other approvals materialize, says the analyst. Maris thinks that even with today's rally, Mylan shares still have more than 10% additional upside potential to reach fair value.
11/15/18
ARGS
11/15/18
UPGRADE
ARGS
Buy
Mylan upgraded to Buy from Hold at Argus
ENDP Endo
$12.39

-0.14 (-1.12%)

11/09/18
ADAM
11/09/18
UPGRADE
Target $20
ADAM
Buy
Endo upgraded to Buy from Hold at Canaccord
Canaccord analyst Dewey Steadman upgraded Endo to Buy from Hold following its "beat and raise" quarter. He noted the strength was in its injectables and branded businesses and sees the recent pullback in the shares as a buying opportunity. Stedman raised his price target to $20 from $16 on Endo shares.
11/09/18
SBSH
11/09/18
NO CHANGE
Target $19
SBSH
Buy
Citi confused by post-earnings selloff in Endo shares
Citi analyst Liav Abraham admits she's "somewhat confused" by the selloff in shares of Endo International following the company's Q3 results. The company posted a "solid beat-and-raise quarter," which was accompanied by "constructive commentary" by management on the fundamentals of both the business and the generics industry, Abraham tells investors in a research note. She continues to see upside to Street estimates, though acknowledges the lack of color provided on the earnings call regarding dynamics heading into 2019 "could have led to some frustration amongst investors." The analyst keeps a Buy rating on Endo with a $19 price target.
11/08/18
HCWC
11/08/18
NO CHANGE
Target $81
HCWC
Buy
BioSpecifics price target raised to $81 from $72 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for BioSpecifics Technologies (BSTC) to $81 after Endo International (ENDP) reported positive results from two identical Phase 3 trials of Collagenase Clostridium Histolyticum, or Xiaflex, for the treatment of cellulite. Earlier this month, BioSpecifics reported positive top-line data from the Phase 1 trial of CCH for the treatment of uterine fibroids, says the analyst. He believes Endo's data from 845 women with moderate to severe cellulite in the U.S. could be a "catalytic milestone" for both Endo and BioSpecifics as there is no FDA approved injectable treatment for cellulite in the aesthetics industry. Selvaraju increased the probability of success from 70% to 85% for BioSpecifics' cellulite indication. It is also possible that Endo may acquire BioSpecifics, Selvaraju tells investors in a research note. He reiterates a Buy rating on BioSpecifics shares.
10/19/18
CANT
10/19/18
NO CHANGE
Target $18
CANT
Neutral
Endo price target raised to $18 from $12 at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen raised her price target for Endo International to $18 after speaking with four physicians that treat up to 50 patients per month for cellulite. All four physicians were "very positive" on Endo's Phase 2 data and expect a good outcome for its Phase 3 study. If CCH is approved, doctors believe it would be the best treatment for both dimpled and wavy/mattress cellulite, Chen tells investors in a research note. The analyst, however, keeps a Neutral rating on Endo, saying she thinks the risk/reward for the company's existing business and new opportunities is already accurately reflected in the stock price.

TODAY'S FREE FLY STORIES

FII

Federated Investors

$24.65

-0.02 (-0.08%)

21:40
12/16/18
12/16
21:40
12/16/18
21:40
Initiation
Federated Investors initiated at Gabelli »

Federated Investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIII

G-III Apparel

$28.68

-0.29 (-1.00%)

21:37
12/16/18
12/16
21:37
12/16/18
21:37
Upgrade
G-III Apparel rating change at Stifel »

G-III Apparel upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLXT

Calyxt

$9.88

0.4 (4.22%)

21:34
12/16/18
12/16
21:34
12/16/18
21:34
Upgrade
Calyxt rating change at Goldman Sachs »

Goldman upgrades Calyxt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLXT

Calyxt

$9.88

0.4 (4.22%)

20:23
12/16/18
12/16
20:23
12/16/18
20:23
Upgrade
Calyxt rating change at Goldman Sachs »

Calyxt upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEQP

Crestwood Equity

$32.29

0.47 (1.48%)

, EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

20:08
12/16/18
12/16
20:08
12/16/18
20:08
Recommendations
Crestwood Equity, EQT Midstream Partners analyst commentary at Goldman Sachs »

Goldman upgrades…

CEQP

Crestwood Equity

$32.29

0.47 (1.48%)

EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITW

Illinois Tool Works

$131.02

-2.26 (-1.70%)

19:57
12/16/18
12/16
19:57
12/16/18
19:57
Downgrade
Illinois Tool Works rating change at Deutsche Bank »

Illinois Tool Works…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWK

Stanley Black & Decker

$118.36

0.46 (0.39%)

19:57
12/16/18
12/16
19:57
12/16/18
19:57
Upgrade
Stanley Black & Decker rating change at Deutsche Bank »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$66.24

-1.04 (-1.55%)

, AET

Aetna

$0.00

(0.00%)

19:31
12/16/18
12/16
19:31
12/16/18
19:31
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

INCY

Incyte

$66.24

-1.04 (-1.55%)

AET

Aetna

$0.00

(0.00%)

ANTM

Anthem

$275.59

-4.93 (-1.76%)

CNC

Centene

$127.55

-5.3 (-3.99%)

CI

Cigna

$205.34

-6.63 (-3.13%)

HNT

Health Net

$0.00

(0.00%)

HUM

Humana

$300.41

-12.09 (-3.87%)

MOH

Molina Healthcare

$131.72

-11.19 (-7.83%)

UNH

UnitedHealth

$265.06

-7.2 (-2.64%)

WCG

WellCare

$236.90

-7.44 (-3.04%)

SNE

Sony

$51.32

-0.88 (-1.69%)

GOOG

Alphabet

$1,041.68

-21.44 (-2.02%)

GOOGL

Alphabet Class A

$1,050.62

-23.36 (-2.18%)

AAPL

Apple

$165.48

-5.45 (-3.19%)

BAC

Bank of America

$24.49

0.1 (0.41%)

BLK

BlackRock

$382.25

-5.29 (-1.37%)

CAT

Caterpillar

$126.78

0.79 (0.63%)

CVX

Chevron

$113.84

-2.15 (-1.85%)

DDAIF

Daimler AG

$0.00

(0.00%)

DAL

Delta Air Lines

$53.50

-0.03 (-0.06%)

ET

Energy Transfer LP

$14.08

-0.5 (-3.43%)

TOL

Toll Brothers

$32.23

-0.4 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 10

    Jan

  • 29

    Jan

  • 05

    Feb

  • 12

    Feb

  • 19

    Feb

  • 24

    Feb

  • 03

    Mar

EQT

EQT Corporation

$19.40

-0.78 (-3.87%)

18:54
12/16/18
12/16
18:54
12/16/18
18:54
Periodicals
EQT's board to seek meeting with Rice brothers, Reuters reports »

EQT Corporation's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

, EQGP

EQGP Holdings

$19.94

0.02 (0.10%)

18:31
12/16/18
12/16
18:31
12/16/18
18:31
Downgrade
EQT Midstream Partners, EQGP Holdings rating change at Goldman Sachs »

EQT Midstream downgraded…

EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

EQGP

EQGP Holdings

$19.94

0.02 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEQP

Crestwood Equity

$32.29

0.47 (1.48%)

18:28
12/16/18
12/16
18:28
12/16/18
18:28
Upgrade
Crestwood Equity rating change at Goldman Sachs »

Crestwood Equity upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$66.24

-1.04 (-1.55%)

17:52
12/16/18
12/16
17:52
12/16/18
17:52
Hot Stocks
Innovent, Incyte announce agreement for three clinical-stage candidates in China »

Incyte and Innovent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

NSANY

Nissan

$0.00

(0.00%)

, RNLSY

Renault

$0.00

(0.00%)

17:14
12/16/18
12/16
17:14
12/16/18
17:14
Periodicals
Renault seeking Nissan shareholder meeting amid Ghosn crisis, Reuters says »

Renault (RNLSY) requested…

NSANY

Nissan

$0.00

(0.00%)

RNLSY

Renault

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

T

AT&T

$30.24

0.33 (1.10%)

, CMCSA

Comcast

$36.32

-0.43 (-1.17%)

16:48
12/16/18
12/16
16:48
12/16/18
16:48
Hot Stocks
Box Office Battle: 'Spider-Verse' wins weekend with $35M »

Sony's (SNE)…

T

AT&T

$30.24

0.33 (1.10%)

CMCSA

Comcast

$36.32

-0.43 (-1.17%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$51.32

-0.88 (-1.69%)

FOX

21st Century Fox

$48.79

-0.09 (-0.18%)

FOXA

21st Century Fox

$49.06

-0.07 (-0.14%)

LGF.A

Lionsgate

$15.59

-0.16 (-1.02%)

DIS

Disney

$112.21

-1.17 (-1.03%)

VIAB

Viacom

$28.56

-0.31 (-1.07%)

VIA

Viacom

$31.23

-0.4 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 30

    Jan

  • 20

    Mar

ELGX

Endologix

$0.71

0.0232 (3.39%)

16:17
12/16/18
12/16
16:17
12/16/18
16:17
Conference/Events
Endologix to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRPO

Precipio

$0.19

-0.0111 (-5.63%)

16:11
12/16/18
12/16
16:11
12/16/18
16:11
Conference/Events
Precipio to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSB

Mesabi Trust

$25.15

-1.1 (-4.19%)

16:08
12/16/18
12/16
16:08
12/16/18
16:08
Conference/Events
Mesabi Trust to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNT

Melinta Therapeutics

$1.19

-0.1 (-7.75%)

16:02
12/16/18
12/16
16:02
12/16/18
16:02
Conference/Events
Melinta Therapeutics to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$75.63

-1.32 (-1.72%)

15:55
12/16/18
12/16
15:55
12/16/18
15:55
Periodicals
Exxon Mobil shareholders call for greenhouse gas reduction targets, Reuters says »

A number of institutional…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANTM

Anthem

$275.59

-4.93 (-1.76%)

, CNC

Centene

$127.55

-5.3 (-3.99%)

13:16
12/16/18
12/16
13:16
12/16/18
13:16
Periodicals
Health stocks preparing for market jolt after Obamacare ruling, Bloomberg says »

U.S. health-care stocks…

ANTM

Anthem

$275.59

-4.93 (-1.76%)

CNC

Centene

$127.55

-5.3 (-3.99%)

CI

Cigna

$205.34

-6.63 (-3.13%)

UNH

UnitedHealth

$265.06

-7.2 (-2.64%)

HUM

Humana

$300.41

-12.09 (-3.87%)

WCG

WellCare

$236.90

-7.44 (-3.04%)

MOH

Molina Healthcare

$131.72

-11.19 (-7.83%)

HNT

Health Net

$0.00

(0.00%)

AET

Aetna

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

  • 05

    Feb

  • 19

    Feb

JELD

Jeld-Wen

$14.27

-0.46 (-3.12%)

13:02
12/16/18
12/16
13:02
12/16/18
13:02
Hot Stocks
Jeld-Wen announces final ruling in Steves & Sons litigation, to appeal decision »

Jeld-Wen announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRA

Atara Biotherapeutics

$41.78

-0.74 (-1.74%)

12:55
12/16/18
12/16
12:55
12/16/18
12:55
Hot Stocks
Atara Biotherapeutics presents positive efficacy, safety results for EBV + LMS »

Atara Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BGNE

BeiGene

$133.95

2.595 (1.98%)

12:41
12/16/18
12/16
12:41
12/16/18
12:41
Hot Stocks
BeiGene announces updated Phase 1A/1B data on tislelizumab »

BeiGene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JELD

Jeld-Wen

$14.27

-0.46 (-3.12%)

12:35
12/16/18
12/16
12:35
12/16/18
12:35
Hot Stocks
Jeld-Wen ordered to divest Pennsylvania plant to restore competition »

Federal Judge Robert…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$52.11

-1.54 (-2.87%)

, RHHBY

Roche

$0.00

(0.00%)

04:55
12/16/18
12/16
04:55
12/16/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO Immuno-Oncology…

BMY

Bristol-Myers

$52.11

-1.54 (-2.87%)

RHHBY

Roche

$0.00

(0.00%)

CELG

Celgene

$68.20

-1.55 (-2.22%)

MRK

Merck

$76.50

-1.94 (-2.47%)

PFE

Pfizer

$43.84

-0.71 (-1.59%)

FLDM

Fluidigm

$7.79

-0.39 (-4.77%)

NEO

NeoGenomics

$13.25

-0.18 (-1.34%)

SGEN

Seattle Genetics

$60.46

-0.5 (-0.82%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

IMV

IMV Inc

$5.65

-0.14 (-2.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 24

    Dec

  • 29

    Dec

  • 11

    Jan

  • 11

    Jan

  • 24

    Jan

  • 16

    Feb

  • 18

    Mar

  • 20

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.